Dermacyd Femina Pocket BR (Lactic Acid)- Acceptability.

Phase 3CompletedNCT00794612

Sanofi30 enrolled

Overview

The purpose of this study is to prove the safety of the gynaecological formulation in normal conditions of use.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Hygiene

Interventions

Dermacyd Femina Pocket BR (Lactic Acid)DRUG

Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: * Integral skin test in the region; * To use products of the same category; Exclusion criteria: * Lactation or gestation; * Use of anti-inflammatory, anti-histaminic or immunosuppressant drugs; * Cutaneous disease (local or spread) in the evaluation area; * Pathology which may cause immunity depression, such as HIV, diabetes; * Endocrine pathology * Solar exposure 15 days before evaluation; * Treatment until four months before the selection. * Allergic or atopic history to cosmetics products The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis Administrative Office

São Paulo, Brazil

Outcomes

Primary Outcomes

Absence of irritation

Time frame: From the start to the end of the study

Good acceptability

Time frame: From the start to the end of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.